See more : Camlin Fine Sciences Limited (CAMLINFINE.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Amicus Therapeutics, Inc. (FOLD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amicus Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Polycab India Limited (POLYCAB.NS) Income Statement Analysis – Financial Results
- North Atlantic Smaller Companies Investment Trust PLC (NAS.L) Income Statement Analysis – Financial Results
- QuantaSing Group Ltd (QSG) Income Statement Analysis – Financial Results
- Tlou Energy Limited (TOU.AX) Income Statement Analysis – Financial Results
- Villeroy & Boch AG (VLBOF) Income Statement Analysis – Financial Results
Amicus Therapeutics, Inc. (FOLD)
About Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 399.36M | 329.23M | 305.51M | 260.89M | 182.24M | 91.25M | 36.93M | 4.96M | 0.00 | 1.22M | 363.00K | 18.41M | 21.43M | 922.00K | 64.36M | 14.97M | 1.78M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 37.33M | 38.60M | 34.47M | 31.04M | 21.96M | 14.40M | 6.24M | 833.00K | 1.83M | 0.00 | 13.49M | 20.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 362.03M | 290.63M | 271.05M | 229.84M | 160.27M | 76.84M | 30.69M | 4.13M | -1.83M | 1.22M | -13.13M | -1.97M | 21.43M | 922.00K | 64.36M | 14.97M | 1.78M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 90.65% | 88.28% | 88.72% | 88.10% | 87.95% | 84.21% | 83.11% | 83.20% | 0.00% | 100.00% | -3,616.80% | -10.68% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 152.38M | 276.68M | 272.05M | 308.44M | 286.38M | 270.90M | 149.31M | 104.79M | 76.94M | 47.62M | 41.94M | 50.27M | 50.86M | 39.04M | 48.08M | 37.76M | 31.07M | 33.63M | 13.65M | 0.00 | 4.43M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 127.20M | 0.00 | 71.15M | 47.27M | 20.72M | 18.89M | 19.36M | 19.88M | 15.66M | 19.97M | 19.67M | 15.28M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 275.27M | 213.04M | 192.71M | 156.41M | 169.86M | 127.20M | 88.67M | 71.15M | 47.27M | 20.72M | 18.89M | 19.36M | 19.88M | 15.66M | 19.97M | 19.67M | 15.28M | 12.28M | 6.88M | 0.00 | 0.00 |
| Other Expenses | 0.00 | 5.34M | 6.21M | 8.85M | 4.78M | -5.63M | 6.01M | -4.79M | -80.00K | -77.00K | 1.72M | 21.00K | 1.59M | 2.06M | 2.13M | 1.49M | 1.24M | 0.00 | 0.00 | -8.81M | 0.00 |
| Operating Expenses | 427.65M | 495.06M | 470.97M | 473.70M | 461.01M | 402.32M | 241.57M | 179.19M | 126.05M | 69.89M | 62.56M | 71.34M | 72.32M | 56.76M | 70.19M | 58.92M | 47.59M | 46.86M | 20.83M | -8.81M | 6.60M |
| Cost & Expenses | 472.85M | 533.66M | 505.43M | 504.74M | 482.98M | 416.72M | 247.81M | 180.02M | 126.05M | 69.89M | 62.56M | 71.34M | 72.32M | 56.76M | 70.19M | 58.92M | 47.59M | 46.86M | 20.83M | -8.81M | 6.60M |
| Interest Income | 7.08M | 3.02M | 509.00K | 3.23M | 10.25M | 10.46M | 4.10M | 1.60M | 929.00K | 223.00K | 174.00K | 316.00K | 160.00K | 156.00K | 997.00K | 4.82M | 0.00 | 1.99M | 609.52K | 0.00 | 5.00K |
| Interest Expense | 50.15M | 37.12M | 32.47M | 22.43M | 18.87M | 22.40M | 17.24M | 5.40M | 1.58M | 1.48M | 46.00K | 89.00K | 148.00K | 260.00K | 278.00K | 218.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 7.87M | 5.34M | 6.21M | 8.85M | 4.78M | 4.22M | 3.59M | 3.24M | 1.83M | 1.55M | 1.72M | 1.71M | 1.59M | 2.06M | 2.13M | 1.49M | 1.24M | 952.45K | 667.38K | 0.00 | 132.00K |
| EBITDA | -92.08M | -199.58M | -202.87M | -242.98M | -332.26M | -322.47M | -428.29M | -195.14M | -128.71M | -67.01M | -61.38M | -50.24M | -46.54M | -53.76M | -4.16M | -37.64M | -44.57M | -44.70M | -20.20M | -8.81M | -6.47M |
| EBITDA Ratio | -23.06% | -58.28% | -64.19% | -89.14% | -180.52% | -346.79% | -533.94% | -3,529.85% | 0.00% | -5,471.49% | -16,611.57% | -276.41% | -229.27% | -5,816.05% | -4.19% | -283.71% | -2,489.85% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -73.49M | -204.43M | -199.92M | -243.85M | -300.74M | -328.78M | -441.99M | -181.89M | -130.44M | -68.70M | -64.18M | -52.93M | -50.89M | -55.84M | -7.35M | -43.96M | -45.81M | -46.86M | -20.83M | -8.81M | -6.60M |
| Operating Income Ratio | -18.40% | -62.09% | -65.44% | -93.47% | -165.03% | -360.32% | -1,196.82% | -3,668.62% | 0.00% | -5,612.83% | -17,680.72% | -287.50% | -237.41% | -6,056.18% | -11.42% | -293.69% | -2,567.54% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -76.61M | -37.61M | -41.63M | -30.40M | -55.17M | -23.61M | -7.14M | -21.89M | -6.07M | -1.34M | 1.04M | 901.00K | 2.85M | -237.00K | 783.00K | 4.60M | 4.64M | 514.36K | 247.27K | 0.00 | -168.00K |
| Income Before Tax | -150.10M | -242.04M | -241.55M | -274.25M | -355.91M | -349.09M | -449.12M | -203.78M | -132.12M | -70.04M | -63.15M | -52.03M | -48.04M | -56.08M | -6.57M | -39.36M | -41.17M | -46.34M | -20.58M | 0.00 | -6.77M |
| Income Before Tax Ratio | -37.59% | -73.52% | -79.06% | -105.12% | -195.30% | -382.58% | -1,216.14% | -4,110.15% | 0.00% | -5,722.14% | -17,395.32% | -282.60% | -224.13% | -6,081.89% | -10.20% | -262.95% | -2,307.57% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.48M | -5.47M | 8.91M | 2.60M | 478.00K | -94.00K | -165.12M | -3.74M | 1.50M | -1.11M | -3.51M | -3.25M | -3.63M | -1.14M | 278.00K | 0.00 | 351.00K | -514.36K | -611.80K | 8.81M | 0.00 |
| Net Income | -151.58M | -236.57M | -250.46M | -276.85M | -356.39M | -349.00M | -284.00M | -200.04M | -132.12M | -68.93M | -59.63M | -48.79M | -44.41M | -54.94M | -6.57M | -39.36M | -41.17M | -46.34M | -19.97M | -8.81M | -6.77M |
| Net Income Ratio | -37.96% | -71.85% | -81.98% | -106.12% | -195.56% | -382.48% | -769.03% | -4,034.73% | 0.00% | -5,631.21% | -16,427.82% | -264.98% | -207.20% | -5,958.35% | -10.20% | -262.95% | -2,307.57% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.51 | -0.82 | -0.92 | -1.07 | -1.48 | -1.88 | -1.85 | -1.49 | -1.20 | -0.93 | -1.16 | -1.07 | -1.28 | -1.98 | -0.29 | -1.75 | -3.11 | -62.97 | -48.69 | -28.64 | -22.01 |
| EPS Diluted | -0.51 | -0.82 | -0.92 | -1.07 | -1.48 | -1.88 | -1.85 | -1.49 | -1.20 | -0.93 | -1.16 | -1.07 | -1.28 | -1.98 | -0.29 | -1.75 | -3.11 | -62.97 | -48.69 | -28.64 | -22.01 |
| Weighted Avg Shares Out | 295.16M | 289.06M | 271.42M | 258.87M | 240.42M | 185.79M | 153.36M | 134.40M | 109.92M | 74.44M | 51.29M | 45.57M | 34.57M | 27.73M | 22.62M | 22.49M | 13.24M | 735.97K | 410.22K | 307.54K | 307.54K |
| Weighted Avg Shares Out (Dil) | 295.16M | 289.06M | 271.42M | 258.87M | 240.42M | 185.79M | 153.36M | 134.40M | 109.92M | 74.44M | 51.29M | 45.57M | 34.57M | 27.73M | 22.62M | 22.49M | 13.24M | 735.97K | 410.22K | 307.54K | 307.54K |
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024
PRINCETON, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November.
Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth
Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024
PRINCETON, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 6, 2024, at 8:30 a.m. ET to discuss financial results for...
Best Momentum Stocks to Buy for October 24th
FOLD, CLPR and HROW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 24, 2024.
5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, BPMC, CRSP, FOLD and VRNA well in this volatile sector.
New Strong Buy Stocks for October 24th
CLPR, HROW, FOLD, GTLB and TCOM have been added to the Zacks Rank #1 (Strong Buy) List on October 24, 2024.
American Citizens Abroad (ACA) joins amicus brief supporting voting by U.S. citizens overseas
WASHINGTON, Oct. 21, 2024 (GLOBE NEWSWIRE) -- American Citizens Abroad (ACA) has joined parties opposing actions which would narrow the ability of U.S. citizens living overseas to vote. In Pennsylvania, steps have been taken by state officials to make it...
3 Attractive Biotechs With Recent Positives
The small cap biotech sector is trading close to the same levels that it was five years ago. Straight equity holdings have threaded water in this space over the past half decade. However, given the lucrative option premiums available against...
Why Amicus Therapeutics (FOLD) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amicus: Teva Settlement Clears Revenue Path Forward For Galafold
Amicus Therapeutics settled litigation with Teva, preventing a generic version of Galafold for Fabry Disease until 2037, ensuring revenue growth. Pombiliti + Opfolda approved for late-onset Pompe Disease, with potential label expansion to children and infants with successful studies, boosting...
Source: https://incomestatements.info
Category: Stock Reports